← Astellas Pharma overview

Astellas Pharma vs Roche: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Astellas Pharma Inc. (4503.JP)

Q3 2026
▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

  • FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.

    A new US approval directly expands the market for an Astellas product, a core driver of future revenue.

  • Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.

    Earnings and guidance are the most direct fundamental driver of the share price.

  • Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.

    A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.

  • Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.

    The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

August 2026
▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

  • FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.

    A new US approval directly expands the market for an Astellas product, a core driver of future revenue.

  • Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.

    Earnings and guidance are the most direct fundamental driver of the share price.

  • Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.

    A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.

  • Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.

    The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

Latest
▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

  • FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.

    A new US approval directly expands the market for an Astellas product, a core driver of future revenue.

  • Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.

    Earnings and guidance are the most direct fundamental driver of the share price.

  • Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.

    A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.

  • Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.

    The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

Roche Holding AG (ROP.SW)

Q3 2026
▲2▼2

Roche Q3: Pipeline Wins, Alzheimer's Progress, But Profit Hit by Franc and Trial Halts

  • Alzheimer's blood test and strong data Roche reported strong Alzheimer's data and received FDA clearance for an Alzheimer's blood test, plus expanded HER2 testing. These advances could open new revenue streams in diagnostics and treatment.

    New positive developments in Alzheimer's and diagnostics that could drive future growth.

  • Nurix deal and Phase III wins A $2.3bn Nurix deal and multiple Phase III wins, including Vabysmo's durable eye data, strengthened Roche's pipeline. Better-than-expected H1 earnings and reaffirmed guidance boosted confidence.

    New partnership and clinical successes that reinforce growth prospects.

  • Profit drop and trial halts H1 net profit fell 6–7% due to a strong Swiss franc, and two Huntington's studies plus a partnered BioNTech cancer vaccine trial were halted. These setbacks weighed on sentiment.

    New negative events that directly impacted financials and pipeline confidence.

  • Tariffs and competitive pressures US tariffs on EU drugs threatened margins, while competition, Medicare pricing, China pressures, and obesity-market execution remained concerns. Lilly and Novo's leadership added to the challenges.

    Ongoing external and competitive risks that could limit upside.

September 2026
▲2▼1

Roche's pipeline surges with FDA wins and Phase III successes

  • Multiple Phase III wins and regulatory advances Roche reported Phase III successes in lung cancer (Tam-Peli), follicular lymphoma (Lunsumio), IgA nephropathy (sefaxersen), and obesity/diabetes (enicepatide), plus Priority Review for Enspryng in MOGAD and European label expansions for Ocrevus and Susvimo.

    These pipeline wins broaden Roche's treatment portfolio and support future revenue growth.

  • New discovery partnerships Roche formed new discovery partnerships with Dualitas, Atavistik, and Earendil, investing in early-stage science to replenish its pipeline and access external innovation.

    These deals show Roche's commitment to long-term growth through external innovation.

  • Competitive and pricing pressures persist Novartis competition in MS, US Medicare pricing discouraging a breast-cancer launch, and the discontinued obesity drug emugrobart weigh on Roche. China and obesity pricing/execution pressure, plus Lilly/Novo leadership, remain material risks.

    These counterweights highlight ongoing challenges that could limit Roche's growth.

Latest
▲3▼1

Roche's pipeline wins and new deals outweigh one obesity setback

  • Roche adds two new drug-discovery partnerships Roche signed collaborations with Dualitas (bispecific antibodies, up to $1 billion) and Atavistik Bio (allosteric medicines, up to $1.9 billion), plus an AI cancer-antibody deal with Earendil Labs. These add future pipeline assets at modest upfront cost, supporting long-term growth expectations.

    New licensing deals expand Roche's pipeline and are a core driver of future revenue.

  • European approvals widen Ocrevus and Susvimo labels CHMP backed Ocrevus for children and teens with relapsing MS, and the European Commission approved Susvimo for a common cause of vision loss in older people. Both expand the patient pool for existing drugs, adding revenue in Europe.

    New regulatory approvals directly expand market access and sales for Roche medicines.

  • Fenebrutinib and giredestrant advance toward US approval The FDA accepted Roche's fenebrutinib application for two forms of MS under priority review, and accepted giredestrant filings in breast cancer after Phase III data showed a 44% cut in progression risk. Both could become significant new products.

    Late-stage regulatory filings are key milestones that can convert pipeline promise into revenue.

  • Roche halts obesity drug emugrobart; competition and pricing pressure persist Roche discontinued emugrobart (GYM329) for obesity, returning rights to Chugai, which hit a year-to-date low. Analysts also flag execution and pricing pressure in China and obesity, where Eli Lilly and Novo Nordisk lead. This is a real counterweight to the pipeline wins.

    A pipeline failure and competitive pressure are the main negatives weighing on Roche's outlook.

▲4▼1

Roche's pipeline wins offset US pricing risk

  • Lung cancer drug Tam-Peli wins Phase III Roche's licensed Tam-Peli cut death risk by 54% in relapsed small-cell lung cancer, with strong survival and response gains. Roche holds worldwide rights outside China, so this supports a future growth driver and lifts confidence in its pipeline.

    A major late-stage win that adds a new potential cancer treatment to Roche's pipeline.

  • Lunsumio combo succeeds in follicular lymphoma Lunsumio plus Revlimid met its Phase III goal in follicular lymphoma, improving progression-free survival versus standard care. This supports full approval and a broader use, strengthening Roche's blood-cancer franchise and future sales.

    A confirmatory trial win that could expand an approved drug's label and revenue.

  • Obesity drug enicepatide hits Phase II goals Roche's once-weekly enicepatide met both goals in a mid-stage trial, cutting blood sugar and weight strongly. This advances its obesity/diabetes pipeline into Phase III, opening a large new market despite rising competition.

    A key pipeline asset showing strong results in a huge potential market.

  • Kidney disease drug sefaxersen succeeds Genentech's sefaxersen met its Phase III goal in IgA nephropathy, sharply reducing protein in urine with best-in-class potential. This adds a promising kidney-disease treatment to Roche's late-stage pipeline, supporting future growth.

    Another late-stage pipeline win that broadens Roche's potential treatment portfolio.

  • US Medicare pricing pressure may delay launches Roche said it may not launch a new oral breast cancer drug, citing US Medicare price alignment that cuts incentives. This regulatory risk could reduce future revenue from new medicines and shows how US pricing policy weighs on Roche's plans.

    A concrete regulatory threat that could limit Roche's ability to launch and profit from new drugs.

▲3▼1

Roche's Diagnostics and Drug Pipeline Advance, Offsetting Competition

  • Alzheimer's Blood Test FDA Clearance FDA cleared Roche and Lilly's Elecsys pTau217 blood test for Alzheimer's, available on Roche's 4,500 US lab machines. This opens a large new testing market and strengthens Roche's diagnostics leadership, supporting future revenue growth.

    This is a new regulatory win that expands Roche's diagnostics franchise and addresses a major unmet need.

  • Enspryng Priority Review for MOGAD FDA granted Priority Review to Roche's Enspryng for MOGAD, a rare autoimmune disease with no approved treatments. If approved, it would be first-in-class, adding a new growth driver and reinforcing Roche's neuroscience portfolio.

    This is a new regulatory milestone that could lead to a first-in-class therapy and new sales.

  • Blood-Cancer Deal with Simcere Roche committed $75 million upfront for global rights to Simcere's experimental blood-cancer drug SIM0660, in a deal worth up to $1.53 billion. The low upfront cost limits risk while adding a potential future pipeline asset.

    This is a new business development move that expands Roche's oncology pipeline with limited near-term financial risk.

  • Novartis Competition in MS Novartis's remibrutinib showed positive Phase 3 results in multiple sclerosis, with analysts estimating $3 billion in peak sales. This could challenge Roche's BTK inhibitor in MS, creating competitive pressure on future sales.

    This is a new competitive threat that could limit Roche's market share in multiple sclerosis.

August 2026
▲3▼1

Roche's diagnostics win big; cancer vaccine setback offsets

  • Alzheimer's blood test cleared by FDA Roche won FDA clearance for the first blood test that helps diagnose Alzheimer's amyloid buildup, usable on its 4,500 US lab machines. This opens a large new testing market and strengthens Roche's diagnostics leadership, a clear positive for future revenue.

    It is the period's biggest new approval and a first-of-its-kind product, directly lifting Roche's growth outlook.

  • HER2 cancer tests approved for wider use FDA expanded approval of Roche's HER2 companion tests to guide treatment in gastroesophageal cancer, a hard-to-treat disease with no prior approved test. This widens the patient pool for Roche's diagnostics and supports its personalized-medicine franchise.

    A new regulatory win that broadens Roche's diagnostic portfolio and adds revenue potential.

  • Vabysmo shows strong two-year eye data Roche's Vabysmo kept improving vision and retinal health in a severe eye disease over two years, with most patients needing treatment only every 20 weeks. Longer dosing intervals make the drug more attractive versus rivals, supporting sales growth.

    New clinical data strengthens the case for a key Roche drug and its competitive position.

  • Partnered cancer vaccine trial halted BioNTech stopped a mid-stage trial of an mRNA cancer vaccine developed with Roche after a safety board saw worse survival in one arm. This removes a hoped-for pipeline win and dents confidence in Roche's cancer vaccine bet.

    It is the period's main negative, a real counterweight to the diagnostic wins.

▲3▼1

Roche's diagnostics win big; cancer vaccine setback offsets

  • Alzheimer's blood test cleared by FDA Roche won FDA clearance for the first blood test that helps diagnose Alzheimer's amyloid buildup, usable on its 4,500 US lab machines. This opens a large new testing market and strengthens Roche's diagnostics leadership, a clear positive for future revenue.

    It is the period's biggest new approval and a first-of-its-kind product, directly lifting Roche's growth outlook.

  • HER2 cancer tests approved for wider use FDA expanded approval of Roche's HER2 companion tests to guide treatment in gastroesophageal cancer, a hard-to-treat disease with no prior approved test. This widens the patient pool for Roche's diagnostics and supports its personalized-medicine franchise.

    A new regulatory win that broadens Roche's diagnostic portfolio and adds revenue potential.

  • Vabysmo shows strong two-year eye data Roche's Vabysmo kept improving vision and retinal health in a severe eye disease over two years, with most patients needing treatment only every 20 weeks. Longer dosing intervals make the drug more attractive versus rivals, supporting sales growth.

    New clinical data strengthens the case for a key Roche drug and its competitive position.

  • Partnered cancer vaccine trial halted BioNTech stopped a mid-stage trial of an mRNA cancer vaccine developed with Roche after a safety board saw worse survival in one arm. This removes a hoped-for pipeline win and dents confidence in Roche's cancer vaccine bet.

    It is the period's main negative, a real counterweight to the diagnostic wins.

July 2026
▲3▼1

Roche gains on pipeline wins and earnings despite profit dip and tariffs

  • Pipeline and diagnostic advances Roche reported positive Alzheimer's data, progress on a blood test, a new TB test, a lupus submission, FDA priority review for Gazyva, and EU backing for Susvimo. These advances support future sales growth.

    These pipeline and diagnostic wins were key positive drivers during the period.

  • Nurix deal and analyst support Roche agreed to a $2.3bn deal with Nurix for blood-cancer drugs, and UBS favored Roche over AI. The deal expands the pipeline, while analyst backing boosted investor confidence.

    The Nurix acquisition and UBS preference were notable positive developments.

  • Earnings beat and reaffirmed guidance Shares jumped 5% after Roche reaffirmed guidance and reported better-than-expected H1 earnings, helped by a lower generic-loss forecast. This reassured investors about the company's outlook.

    The earnings beat and guidance reaffirmation directly lifted the stock.

  • Profit dip, study halts, competition, tariffs H1 net profit fell 6–7% on the strong franc; two Huntington's studies were discontinued; Outlook Therapeutics' Lytenava approval adds eye-disease competition; and new US tariffs on EU drugs threaten exports and margins.

    These setbacks weighed on sentiment and pose risks to future performance.

▲3▼1

Roche gains on outlook, drug wins, but tariffs and competition weigh

  • Roche reiterates 2026 outlook, shares jump 5% Roche reaffirmed its full-year guidance, reassuring investors and sending shares up about 5%. This signals confidence in future earnings and reduces uncertainty, supporting the stock price.

    This is the biggest single-day move and directly answers why the stock moved.

  • New US tariffs on EU drugs threaten Roche's exports Trump announced phased tariffs on generic drug imports, with rates up to 200% by 2029, and new 10-12.5% tariffs on EU goods including pharmaceuticals. As a major EU drug exporter, Roche faces higher costs and potential sales pressure, a negative for the stock.

    This is a new, material risk that could hurt Roche's US sales and profitability.

  • Roche wins FDA clearance for diagnostic and EU backing for eye implant Roche received FDA clearance for its cobas BV/CV assay and EU recommendation for Susvimo eye implant. These expand its diagnostics and treatment offerings, adding future revenue streams and strengthening its pipeline.

    New approvals directly support future sales growth and pipeline strength.

  • Nurix and Labcorp advances boost Roche's pipeline and diagnostics Nurix enrolled the first patient in a Phase 3 trial of bexobrutideg with Roche, and Labcorp launched Roche's PTEN companion diagnostic nationwide. These advances validate Roche's collaboration strategy and expand its diagnostic reach, supporting long-term growth.

    These are new positive developments that show pipeline and diagnostic progress.

▲2▼1

Roche's H1 profit falls on franc, but pipeline and diagnostics advance

  • Strong Swiss franc cuts reported H1 profit Roche's first-half net profit fell 6-7% to about 6.9-7.3 billion francs, mainly because the strong Swiss franc reduced the value of overseas sales. This headline weakness can pressure the stock, even though sales rose 6% in constant currency.

    This is the main negative force this period, explaining why reported earnings look weak.

  • Lower generic hit and better-than-expected earnings lift shares Roche cut its expected 2026 generic sales loss to about 600 million francs from 1 billion, and first-half earnings beat expectations. Shares jumped 3.2% as investors saw less near-term revenue erosion, though full-year guidance was unchanged.

    This is the key positive surprise that drove the stock up on results day.

  • New drug and diagnostic approvals expand future sales Roche won FDA priority review for Gazyva in a kidney disease, CHMP backing for Susvimo eye implant in Europe, and FDA clearance for a new vaginitis test. These add future revenue streams and strengthen its pipeline and diagnostics franchise.

    These regulatory wins are new and support long-term growth, a core part of the investment case.

  • Nurix deal closes, but new eye competition emerges Roche closed its $2.3 billion Nurix collaboration for a blood cancer drug, gaining a promising asset. However, FDA approval of Outlook Therapeutics' Lytenava creates new competition for Roche's Avastin in eye disease, a modest negative.

    This shows both pipeline progress and a competitive threat, giving a balanced view.

▲3

Roche advances Alzheimer's, TB, lupus and AI, but Huntington's setback

  • Alzheimer's data and blood test progress Roche will present long-term trontinemab data and pTau217 blood test results at AAIC 2026, including a Phase III prevention study design. Positive data could boost confidence in its Alzheimer's pipeline and diagnostics, supporting future sales.

    This is new and shows pipeline progress that can drive future revenue.

  • UBS backs Roche as safer bet than AI UBS reiterated overweight on European pharma, preferring Roche among large caps due to improving earnings and low valuations. This can attract more investors, pushing the stock up.

    New analyst endorsement highlights a shift in capital flows toward Roche.

  • New TB test and lupus drug submission Roche received CE Mark for an automated TB test and has submitted obinutuzumab for lupus with FDA decision expected by December 2026. These expand diagnostics and treatment offerings, adding revenue potential.

    New product approvals and regulatory milestones support growth.

  • Nurix deal adds pipeline, but Huntington's failure Roche signed a $2.3 billion deal with Nurix for a promising blood cancer drug, but discontinued two Huntington's disease studies. The deal strengthens the pipeline, while the setback removes a potential therapy, balancing the impact.

    Both a positive pipeline boost and a negative clinical setback occurred this period.

Q2 2026
▲4

Roche's pipeline and diagnostics surge with FDA wins and new products

  • FDA accepts Lunsumio-Polivy combo filing FDA accepted Roche's filing for a chemotherapy-free lymphoma combo that cut progression risk by 59%. If approved, it opens a new treatment option in a hard-to-treat cancer, supporting future sales growth.

    New regulatory milestone that expands Roche's oncology portfolio and potential revenue.

  • FDA priority review for Enspryng in thyroid eye disease FDA granted priority review for Enspryng as a first at-home treatment for thyroid eye disease, with a decision due October 2026. This could add a new indication to an existing drug, boosting its sales potential.

    New regulatory catalyst that could broaden an approved drug's label and revenue.

  • Roche launches AXELIOS 1 gene sequencer, undercutting Illumina Roche launched its own next-generation sequencing platform at $750,000, below Illumina's machines. This challenges Illumina's 70% market share and opens a new growth avenue in the $7.3 billion sequencing market.

    New product launch that enters a large, fast-growing market and pressures a key competitor.

  • Divarasib beats approved KRAS inhibitors in Phase III Genentech's divarasib showed better progression-free and overall survival than current KRAS G12C drugs in lung cancer. Positive late-stage data raise the odds of a new blockbuster and strengthen Roche's pipeline.

    New clinical win that could lead to a best-in-class cancer drug and future revenue.

June 2026
▲4

Roche's pipeline and diagnostics surge with FDA wins and new products

  • FDA accepts Lunsumio-Polivy combo filing FDA accepted Roche's filing for a chemotherapy-free lymphoma combo that cut progression risk by 59%. If approved, it opens a new treatment option in a hard-to-treat cancer, supporting future sales growth.

    New regulatory milestone that expands Roche's oncology portfolio and potential revenue.

  • FDA priority review for Enspryng in thyroid eye disease FDA granted priority review for Enspryng as a first at-home treatment for thyroid eye disease, with a decision due October 2026. This could add a new indication to an existing drug, boosting its sales potential.

    New regulatory catalyst that could broaden an approved drug's label and revenue.

  • Roche launches AXELIOS 1 gene sequencer, undercutting Illumina Roche launched its own next-generation sequencing platform at $750,000, below Illumina's machines. This challenges Illumina's 70% market share and opens a new growth avenue in the $7.3 billion sequencing market.

    New product launch that enters a large, fast-growing market and pressures a key competitor.

  • Divarasib beats approved KRAS inhibitors in Phase III Genentech's divarasib showed better progression-free and overall survival than current KRAS G12C drugs in lung cancer. Positive late-stage data raise the odds of a new blockbuster and strengthen Roche's pipeline.

    New clinical win that could lead to a best-in-class cancer drug and future revenue.

▲4

Roche's pipeline and diagnostics surge with FDA wins and new products

  • FDA accepts Lunsumio-Polivy combo filing FDA accepted Roche's filing for a chemotherapy-free lymphoma combo that cut progression risk by 59%. If approved, it opens a new treatment option in a hard-to-treat cancer, supporting future sales growth.

    New regulatory milestone that expands Roche's oncology portfolio and potential revenue.

  • FDA priority review for Enspryng in thyroid eye disease FDA granted priority review for Enspryng as a first at-home treatment for thyroid eye disease, with a decision due October 2026. This could add a new indication to an existing drug, boosting its sales potential.

    New regulatory catalyst that could broaden an approved drug's label and revenue.

  • Roche launches AXELIOS 1 gene sequencer, undercutting Illumina Roche launched its own next-generation sequencing platform at $750,000, below Illumina's machines. This challenges Illumina's 70% market share and opens a new growth avenue in the $7.3 billion sequencing market.

    New product launch that enters a large, fast-growing market and pressures a key competitor.

  • Divarasib beats approved KRAS inhibitors in Phase III Genentech's divarasib showed better progression-free and overall survival than current KRAS G12C drugs in lung cancer. Positive late-stage data raise the odds of a new blockbuster and strengthen Roche's pipeline.

    New clinical win that could lead to a best-in-class cancer drug and future revenue.

© 2026 MarketDXWhy